Inicio・Lista de Acciones・Edwards Lifesciences Corp

Edwards Lifesciences Corp

Cerrado

SectorSanidad

89.31 0.56

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

87.7

Máximo

89.34

Métricas clave
By Trading Economics
Ingresos	-139M 242M
Ventas	92M 1.7B
P/B Media del Sector	52.869 68.51
BPA	0.78
Margen de beneficios	13.894
Empleados	16,000
EBITDA	20M 520M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+15.63% upside

Dividendos
By Acuity
Próximas Ganancias	29 oct 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.2B 51B
Apertura anterior	88.75
Cierre anterior	89.31

Noticias sobre sentimiento de mercado

By Acuity

94%

7 / 340 Clasificación en Healthcare

Edwards Lifesciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 ago 2026, 19:56 UTC

Edwards Lifesciences shares are lower today, continuing a decline since Tuesday. The stock remains above its 20-day moving average.

4 ago 2026, 19:36 UTC

Edwards Lifesciences shares are higher amid positive market momentum, despite a notable decline in U.S. core factory orders reflecting weakening demand across sectors.

3 ago 2026, 22:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, following a notable decline that reached a session low shortly after the market opened.

31 jul 2026, 19:46 UTC

Edwards Lifesciences shares are lower, reflecting broader market trends amid inflation and interest rate concerns. The stock is trading below its 20-day moving average.

30 jul 2026, 22:06 UTC

Edwards Lifesciences shares are trading lower in after-market hours, reflecting ongoing weakness and uncertainty following the Federal Reserve's interest rate decision.

29 jul 2026, 23:46 UTC

Edwards Lifesciences Corp shares are higher in after-market trading, following four consecutive sessions of gains. No specific news was identified to explain the movement.

28 jul 2026, 18:46 UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

27 jul 2026, 19:41 UTC

Social Media

News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

24 jul 2026, 18:41 UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

23 jul 2026, 23:41 UTC

News

Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

22 jul 2026, 18:46 UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

21 jul 2026, 21:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

20 jul 2026, 19:56 UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Comparación entre iguales

Cambio de precio

Edwards Lifesciences Corp previsión

Precio Objetivo

By TipRanks

15.63% repunte

Estimación a 12 Meses

Media 102.88 USD 15.63%

Máximo 110 USD

Mínimo 85 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Edwards Lifesciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

Comprar

Mantener

Vender

De acuerdo con 19 analistas que ofrecen calificaciones bursátiles a para Edwards Lifesciences Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

7 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.